Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 Outlook
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Strong adjusted operating profitability in medical consumables offsets top-line dental equipment declines, stabilizing full-year earnings visibility for XRAY within the $1.40 to $1.50 EPS guidance range.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factDENTSPLY SIRONA (XRAY) reported Q2 adjusted EPS of $0.52, beating the consensus estimate of $0.36. |
| What else was confirmed? | Reported factRevenues declined 4.1% year-over-year during the quarter. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for XRAY yet — this is the next research task. |
| What would change the assessment? | UnknownMedical device peer earnings read-through — Consumables versus equipment volume trends across dental and surgical suppliers. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · DENTSPLY SIRONA (XRAY) reported Q2 adjusted EPS of $0.52, beating the consensus estimate of $0.36.
- · Revenues declined 4.1% year-over-year during the quarter.
- · The Wellspect Healthcare segment grew 7.1% during the period.
- · XRAY maintained full-year 2026 guidance with expected sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
Public research record
Research framework · page evidenceCompleted event assessment
earnings beat and margin resilience against revenue contraction
| Type | Claim | Scope |
|---|---|---|
| Assumption | DENTSPLY SIRONA (XRAY) reported Q2 adjusted EPS of $0.52, beating the consensus estimate of $0.36. | 2026-09-09 |
| Interpretation | earnings beat and margin resilience against revenue contraction | XRAY |
Countercase, invalidators, and sources
Dental practice capital equipment spending rebounds in the second half, pushing full-year sales to the upper end of the $3.6B guidance range.
- · Medical device peer earnings read-through — Consumables versus equipment volume trends across dental and surgical suppliers.
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · 2026-09-08
What remains unresolved
- Base path
- Cost containment and Wellspect performance keep full-year EPS within the guided $1.40 to $1.50 corridor.
- Adverse path
- Persistent consumer deferral of elective dental procedures drives equipment revenues lower, pressuring segment operating margins.
- Supportive path
- Dental practice capital equipment spending rebounds in the second half, pushing full-year sales to the upper end of the $3.6B guidance range.
- · Medical device peer earnings read-through — Consumables versus equipment volume trends across dental and surgical suppliers.this week
Evidence
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure2026-09-08
“DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS.”
Supports: Dentsply Sirona reported adjusted EPS of $0.52 vs $0.36 consensus, down 4.1% YoY revenue, and reaffirmed FY26 guidance.